EMEA-002146-PIP02-18

Active substance

Palbociclib

Decision number

P/0005/2019

Pharmaceutical form(s)

Route(s) of administration

Oral use

Decision type

W: decision granting a waiver in all age groups for all conditions or indications

Invented name	Ibrance
Active substance	Palbociclib
Therapeutic area	Oncology
Decision number	P/0005/2019
PIP number	EMEA-002146-PIP02-18
Pharmaceutical form(s)	Capsule, hard Age-appropriate oral dosage form Tablet
Condition(s) / indication(s)	Treatment of breast malignant neoplasms
Route(s) of administration	Oral use
Contact for public enquiries	Pfizer Europe MA EEIG Tel. +44 1304 6466 07 E-mail: pip_enquiries@pfizer.com
Decision type	W: decision granting a waiver in all age groups for all conditions or indications